DISCLAIMER: This page is intended for members of the general public in Israel only.
The information provided on this site is intended for general information and education for Israel-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted)
NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series and as a heterologous and homologous booster in adults aged 18 and older previously vaccinated with mRNA vaccines.
Important information
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Israel at health.gov.il.